Orexo Announces Results Confirming The Clinical Profile Of OX17 In Reflux Disease GERD

New clinical data from a phase II study confirms the competitive profile of Orexo's product OX17 in GERD patients, i.e. fast, effective and sustained inhibition of gastric acid production, a prerequisite for effective symptom relief in the patient. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: